New perspectives on developing acute stroke therapy

Annals of Neurology

Volumn 53, Issue 1, 2003, Pages 10-20

  Fisher, Marc ^a   Ratan, Rajiv ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT;

ACUTE DISEASE; BRAIN ISCHEMIA; CELL DAMAGE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT PLANNING;

EID: 0037231768     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10407     Document Type: Review

References (78)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
2. Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke. JAMA 2000;283:2395-2403.
3. Furlan A, Higashida R, Wechsler LA, et al. Intraarterial prourokinase for acute ischemic stroke. The PROACT-2 Study: a randomized controlled trial. JAMA 1999;282:2003-2011.
4. Fisher M, Schaebitz W. An overview of acute stroke therapy. Arch Int Med 2000;160:3196-3206.
5. Fisher M. Characterizing the target of acute stroke treatment. Stroke 1997;28:866-872.
6. Hossmann K-A. Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994;36:557-565.
7. Hakim AM. The cerebral ischemic penumbra. Can J Neurol Sci 1987;14:557-559.
8. Heiss W-D, Graf R, Loftgren J, et al. Repeat position emission tomographic studies in transient middle cerebral artery occlusion in cats: residual perfusion and efficacy of postischemic reperfusion. J Cereb Blood Flow Metab 1997;17:388-400.
9. Baron JC. Mapping the ischemic penumbra with PET: implications for acute stroke treatment. Cerebrovasc Dis 1999;9:193-201.
10. Marchal G, Beaudoin V, Rioux P, et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke. Stroke 1996;27:597-606.
11. Furlan M, Marchal G, Vinder F, et al. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol 1996;40:216-226.
12. Neumann-Haefelin T, Moseley ME, Albers GW, New magnetic resonance imaging methods for cerebrovascular disease: emerging clinical applications. Ann Neurol 2000;31:559-570.
13. Schellinger PD, Fieback JB, Jansen O, et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol 2001;49:460-469.
14. Schlaug G, Benfield A, Baird AE, et al. The ischemic penumbra: operationally defined by diffusion perfusion MRI. Neurology 1999;53:1528-1537.
15. Marks MP, Tong DC, Beaulieu C, et al. Evaluation of early reperfusion and I.V. tPA therapy using diffusion and perfusion-weighted MRI. Neurology 1999;52:1792-1798.
16. Parsons MW, Barber PA, Chalk J, et al. Diffusion and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002;51:28-37.
17. Beaulieu C, Moseley ME. Diffusion-weighted and perfusion-weighted magnetic resonance imaging in clinical stroke. In: Fisher M, Bogousslavsky J, eds. Current review of cerebrovascular disease. 4th ed. Philadelphia: Current Medicine, 2001:59-68.
18. Yamada K, Wu O, Gonzalez RG, et al. Magnetic resonance perfusion-weighted imaging of acute cerebral infarction effect of calculation methods and underlying vasculopathy. Stroke 2002;33:87-94.
19. Ostergaard L, Weiskoff PM, Cheoler DA, et al. High resolution measurement of cerebral blood flow using tracer bolus passages. Part 1. Mathematical approach and statistical analysis. Magn Res Med 1996;36:715-725.
20. Parsons MW, Yang Q, Barber PA, et al. Perfusion magnetic resonance imaging maps in hyperacure stroke. Stroke 2001;32:1581-1587.
21. Neumann-Haefelin T, Wittsack HJ, Wenserski F, et al. Diffusion and perfusion-weighted: the DWI/PWI mismatch region in acute stroke. Stroke 1999;30:1591-1597.
22. Li F, Silva MD, Liu KF, et al. Secondary decline in apparent diffusion coefficient and neurological outcome after a short period of focal brain ischemia in rats. Ann Neurol 2000;48:236-244.
23. Kidwell CS, Saver JL, Martiello J, et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 2000;47:462-469.
24. Fichler J, Forh M, Kucinski T, et al. Severe ADC decreases do not predict irreversible tissue damage in humans. Stroke 2002;33:79-86.
25. Jungreis CA, Yonas H, Firlik AD, Wechsler LR. Advanced CT imaging (functional imaging). Neuroimaging Clin North Am 1999;9:455-464.
26. Koenig M, Kraus M, Theek C, et al. Quantitative assessment of the ischemic brain by means of perfusion-related parameters derived form perfusion CT. Stroke 2001;32:431-437.
27. Lee KH, Cho SJ, Byun HS, et al. Triphasic perfusion computed tomography in acute middle cerebral artery stroke. Arch Neurol 2000;57:990-999.
28. Wintermark M, Bogousslavsky J, Thiren JP, et al. Prognostic accuracy of admission cerebral blood flow measurements by perfusion CT in acute stroke patients. Ann Neurol 2002;51:417-432.
29. Von Kummer R, Allen KL, Helle R, et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology 1997;205:327-333.
30. Fleming D, Walter B. Cannon and homeostasis. Soc Res (New York) 1984;51:609-640.
31. Dawson VL, Dawson TM. Neuronal ischaemic preconditioning. Trends Pharmacol Sci 2000;21:423-424.
32. Hochachka PW, Lutz PL. Mechanism, origin, and evolution of anoxia tolerance in animals. Comp Biochem Physiol B Biochem Mol Biol 2001;130:435-459.
33. Zhou F, Zhu X, Casrellani RJ, et al. Hibernation, a model of neuroprotection Am J Pathol 2001;158:2145-2151.
34. Frerichs KU, Kennedy C, Sokoloff L, Hallenbeck JM. Local cerebral blood flow during hibernation, a model of natural tolerance to "cerebral ischemia." J Cereb Blood Flow Metab 1994;14:193-205
35. Hochachka PW. Defense strategies against hypoxia and hypothermia. Science 1986;231:234-241
36. Miller MJ. Preconditioning for cardioprotection against ischemia reperfusion injury: the roles of nitric oxide, reactive oxygen species, heat shock proteins, reactive hyperemia and antioxidants - a mini review. Can J Cardiol 2001;17:1075-1082
37. Shake JG, Peck EA, Marban E, et al. Pharmacologically induced preconditioning with diazoxide: a novel approach to brain protection. Ann Thorac Surg 2001;72:1849-1854
38. Chen J, Simon R. Ischemic tolerance in the brain. Neurology 1997;48:306-311
39. Ceremi A, Brines ML, Ghezzi P, Cerami CJ. Effects of epoetin alfa on the central nervous system. Semin Oncol 2001;(suppl 8):66-70.
40. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98:4044-4049.
41. Sinor AD, Greenberg DA Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicity Neurosci Lett 2000;290:213-215.
42. Sakkanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998;95:4635-4640.
43. Nagai A, Nakagawa E, Choi HB, et al. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001;60:386-392.
44. Sharp FR, Bergeron M, Bernaudin M. Hypoxia-inducible factor in brain. Adv Exp Med Biol 2001;502:273-291.
45. Bernaudin M, Nedelec AS, Divoux D, et al. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab 2002;22:393-403.
46. DeGracia DJ, Kumar R, Owen CR, et al. Molecular pathways of protein synthesis inhibition during brain reperfusion: implications for neuronal survival or death. J Cereb Blood Flow Metab 2002;22:127-141.
47. Golden WC, Brambrink AM, Traystman RJ, Martin LJ. Failure to sustain recovery of Na, K-ATPase function is a possible mechanism for striatal neurodegeneration in hypoxic-ischemic newborn piglets. Brain Res Mol Brain Res 2001;88:94-102.
48. Rego AC, Ward MW, Nicholls DG. Mitochondria control ampa/kainate receptor-induced cytoplasmic calcium deregulation in rat cerebellar granule cells. J Neurosci 2001;21:1893-1901.
49. 1. J Biol Chem 2001;275:28353-28355.
50. Bredesen DE. Neural apoptosis. Ann Neurol 1995;38:839-851.
51. Lee J-M, Grabb MC, Zipfel GJ, Choi DW. Brain tissue responses to ischemia. J Clin Invest 2000;106:723-731.
52. Multicenter Acute Stroke Trial-Italy (MAST-1) Group. Randomized, controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischemic stroke. Lancet 1995;346:1509-1514.
53. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
54. Hacke W, Kaste M, Fieschi C, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS-2). Lancet 1998;352:1245-1251.
55. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS trial: a randomized controlled trial. JAMA 1999;282:2019-2026.
56. Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-2758.
57. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Stroke 1995;26:254-258.
58. Adams HP, Davis PH, Leira EC, et al. Baseline NIH stroke scale score strongly predicts outcome after stroke. Neurology 1999;53:126-131.
59. Frankel MR, Morgenstern LB, Kwiatkowski T, et al. Predicting prognosis after stroke. Neurology 2000;55:952-959.
60. Stys PK. Anoxic and ischemic injury of myelinated axons in CNS white matter: from mechanistic concepts to therapeutics. J Cereb Blood Flow Metab 1998;18:2-25.
61. Van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
62. Clark WA, Wechsler LR, Sabounjian LA, et al. A phase 3 randomized efficacy trial of 2000 mg citicoline in acute stroke patients. Neurology 2001;57:1595-1602
63. Clark WA, Williams B, Selzer K, et al. A randomized efficacy trial of citicoline in acute ischemic stroke patients. Stroke 1999;30:2592-2597.
64. Clark WA, Warach S, Pettigrew LC, et al. A randomized, dose response trial of citicoline in acute ischemic stroke patients. Neurology 1997;49:671-678.
65. Saver J, Wilterdink J. Choline precursons in acute and subacute stroke: a meta-analysis. Stroke 2002;33:353.
66. Stroke Therapy Academic Industry Roundtable (Fisher M, Chair). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001;32:1598-1606.
67. Hacke W, Brott T, Caplan LR, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 1999;53(suppl):S3-S14.
68. Nilasena DS, Kresowik TF, Wiblin RT, et al. Assessing patterns of tPA use in acute stroke. Stroke 2002;33:354.
69. Grotta JC, Burgin S, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke. Arch Neurol 2001;58:2009-2013.
70. Koennecke HC, Nohr R, Leistner S, Marx P. Intravenous tPA for ischemic stroke: team performance over time, safety and efficacy in a single center, 2 year experience. Stroke 2001;32:1074-1078.
71. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment is associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000;55:1649-1655.
72. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for treatment of acute stroke: the Cleveland area experience. JAMA 2000;283:1145-1150.
73. Stapf C, Marshall RS, Mohr JP, et al. Late intra-arterial thrombolysis. Eur J Med Rev 2000;5:303-306.
74. Tomsick T, Broderick JP, Pancioli A, et al. Combined IV-IA rtPA treatment in major acute ischemic stroke. Stroke 2002;33:359.
75. Zhang L, Zhang ZG, Zhang RL, et al. Postischemic treatment with recombinant tissue plasminogen activator and proteosome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 2001;32:2926-2931.
76. Sharp FR, Lu A, Tang Y, Milhorn DE, Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab 2000;20:1011-1032.
77. Maynard KI, Quinones-Minojosa A, Matek JM. Neuroprotection against ischemia by metabolic inhibition revisited: a comparison of hypothermia, a pharmacologic cocktail and magnesium plus mexiletine. Ann N Y Acad Sci 1999;890:240-254.
78. Culmsee C, Junker V, Wolz P, et al. Lubeluzole protectes hippocampal neurons from excitotoxicity in vitro and reduces brain damage caused by ischemia. Eur J Pharmacol 1998;342:193-201.